Edwards Lifesciences Co. (NYSE:EW) is Ownership Capital B.V.’s 5th Largest Position

Ownership Capital B.V. raised its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 21.3% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 3,489,915 shares of the medical research company’s stock after buying an additional 613,817 shares during the period. Edwards Lifesciences accounts for about 5.9% of Ownership Capital B.V.’s investment portfolio, making the stock its 5th biggest holding. Ownership Capital B.V.’s holdings in Edwards Lifesciences were worth $266,106,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of the company. Vanguard Group Inc. lifted its position in shares of Edwards Lifesciences by 0.6% during the third quarter. Vanguard Group Inc. now owns 51,633,416 shares of the medical research company’s stock valued at $3,577,163,000 after buying an additional 325,808 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Edwards Lifesciences by 9.2% in the 3rd quarter. Wellington Management Group LLP now owns 16,434,401 shares of the medical research company’s stock valued at $1,138,575,000 after purchasing an additional 1,390,427 shares during the last quarter. Brown Advisory Inc. raised its position in shares of Edwards Lifesciences by 5.7% in the 3rd quarter. Brown Advisory Inc. now owns 15,133,146 shares of the medical research company’s stock valued at $1,048,424,000 after purchasing an additional 818,849 shares during the last quarter. Northern Trust Corp raised its position in shares of Edwards Lifesciences by 3.9% in the 3rd quarter. Northern Trust Corp now owns 6,357,473 shares of the medical research company’s stock valued at $440,446,000 after purchasing an additional 241,347 shares during the last quarter. Finally, WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST raised its position in shares of Edwards Lifesciences by 16.8% in the 4th quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,100,000 shares of the medical research company’s stock valued at $312,625,000 after purchasing an additional 590,000 shares during the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of the firm’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $78.29, for a total value of $567,993.95. Following the transaction, the chief financial officer now owns 19,248 shares in the company, valued at approximately $1,506,925.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, VP Donald E. Bobo, Jr. sold 11,000 shares of Edwards Lifesciences stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $85.83, for a total transaction of $944,130.00. Following the transaction, the vice president now owns 39,503 shares in the company, valued at approximately $3,390,542.49. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $78.29, for a total value of $567,993.95. Following the transaction, the chief financial officer now owns 19,248 shares in the company, valued at approximately $1,506,925.92. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 194,004 shares of company stock worth $17,166,254. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock traded down $1.58 during trading on Friday, reaching $86.43. The company had a trading volume of 4,979,943 shares, compared to its average volume of 2,883,164. The firm’s 50-day simple moving average is $90.28 and its 200 day simple moving average is $78.85. Edwards Lifesciences Co. has a 1-year low of $60.57 and a 1-year high of $96.12. The firm has a market capitalization of $52.02 billion, a PE ratio of 37.25, a price-to-earnings-growth ratio of 4.36 and a beta of 1.05. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.40 and a current ratio of 3.38.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. The firm had revenue of $1.60 billion for the quarter, compared to analysts’ expectations of $1.58 billion. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 23.34%. As a group, equities research analysts anticipate that Edwards Lifesciences Co. will post 2.76 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on EW shares. Morgan Stanley increased their price objective on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the company an “overweight” rating in a research report on Thursday, March 21st. Wells Fargo & Company increased their price objective on shares of Edwards Lifesciences from $94.00 to $99.00 and gave the company an “overweight” rating in a research report on Friday. Mizuho raised their price target on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the stock a “buy” rating in a research report on Thursday, April 11th. OTR Global raised shares of Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research report on Tuesday, March 26th. Finally, Royal Bank of Canada raised their price target on shares of Edwards Lifesciences from $95.00 to $101.00 and gave the stock an “outperform” rating in a research report on Monday, April 15th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $93.33.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.